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of current antipsychotic medication is cost-effective despite higher costs of antipsy-
chotic medication. Positive clinical and economic results persisted over 24 months.
PMH35
COST-EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF 
MODERATE AND SEVERE ALZHEIMER’S DISEASE PATIENTS WITH 
AGITATION, AGGRESSION AND PSYCHOSIS—THE UK EXAMPLE
Rive B1, Grishchenko M1, Guilhaume C1, Katona C2, Lamure M3, Livingston G2, Toumi M4, 
Francois C1
1Lundbeck SAS, Issy-Les Moulineaux, France; 2University College London, London, UK; 
3University Claude Bernard Lyon 1, Paris, France; 4University Claude Bernard Lyon 1, Lyon, 
France
OBJECTIVES: To assess the cost-effectiveness of memantine in moderate and severe 
AD patients who exhibit agitation/aggression and psychotic symptoms (APS) from the 
UK National Health Service and Personal Social Services perspective. METHODS: 
The cost-utility analysis was based on 5-year Markov cohort simulations. The model 
evaluated the impact of memantine on time to Full-Time-Care (FTC), Quality-
Adjusted-Life-Years (QALYs) and costs, in pre-FTC patients compared with standard 
care, i.e. no pharmacotherapy or background treatment with acetylcholinesterase 
inhibitors. FTC was deﬁ ned based on locus of care and patient’s physical and func-
tional dependency status. Transition probabilities, baseline characteristics, resource 
utilization volumes, health utility weights and mortality rates were derived from the 
4.5-year London and South-East Region (LASER-AD) epidemiological study. Effec-
tiveness estimates came from a meta-analysis of six large randomised clinical trials. 
Costs covered routine patient management, hospitalization, social community services, 
institutionalization, and medications. Results were reported in EUR (GBP), 2009. The 
model underwent extensive stochastic and one-way sensitivity analyses, testing the 
model assumptions and changes in input parameters. RESULTS: Over ﬁ ve years, 
patients receiving standard care spend on average 78.8 weeks in the pre-FTC state. 
Overall costs in this group were c117,960 (£98,810). QALYs were estimated at 1.49 
(30% of full health). Memantine was associated with a longer time-to-FTC of 11.2 
weeks, QALY gains of 0.07 and cost-savings of c5930 (£4970). Lower costs in the 
memantine group were due to prolonged pre-FTC period. Memantine was more effec-
tive and less costly strategy relative to standard care in 99.98% of simulations. The 
estimated beneﬁ ts and cost savings were almost twice higher than those previously 
estimated in all moderate and severe AD patients, largely due to enhanced efﬁ cacy of 
memantine in APS patients, who, when left untreated, rapidly deteriorate. CONCLU-
SIONS: The model showed that memantine yielded higher beneﬁ ts at no additional 
costs relative to its alternative.
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OBJECTIVES: This analysis investigates the relative efﬁ ciency in the treatment of BD 
with the use atypical antipsychotics (AA): aripiprazole (ARI); olanzapine (OLA); 
quetiapine (QUE); risperidone (RIS); and ziprasidone (ZIP). METHODS: our analysis 
takes into consideration the treatment cost of AA and the impact on hospitalization 
costs associated with each AA. Mean daily dose of each AA, length of treatment and 
the probability of hospitalization for each AA were obtained from a retrospective 
study (90 days of follow-up) in 6,162 BD patients (Jing et al. 2009). The minimum 
acquisition cost per mg. of the mean daily dose, for each AA, is regarded as an efﬁ -
ciency criterion in Hospital Pharmacy Departments. The cost per day of hospitaliza-
tion (c347.90) and the length of hospitalization associated to BD (18.1 days; 
14.5–21.7) were obtained from a Spanish study. RESULTS: after 90 days of follow-up, 
hospitalization rates were higher with OLA (8.7%), QUE (8.5%), RIS (8.6%) and 
ZIP (10.2%) in comparison with ARI (5.9%; 5.8%; 5.7%; 6.5%, respectively). The 
treatment of BD with ARI gave rise to the following cost savings per patient, in relation 
to other AA: c149.31 ARI versus OLA; c33.42 ARI versus QUE; c19.45 ARI versus 
RIS; and c242.22 ARI versus ZIP. a sensitivity analysis tested the following variables: 
minimum daily dose for each AA; maximum daily dose for each AA; length of treat-
ment with AA; and probability of hospitalization for each AA. The sensitivity analysis 
conﬁ rms the cost savings associated with aripiprazole, with the only exception of 
risperidone where the cost saving per patient is almost neutral (c−2.89). CONCLU-
SIONS: using the criterion of cost rationalization based upon the minimum acquisition 
cost per mg. aripiprazole may have economic beneﬁ ts over other AA in terms of lower 
psychiatric treatment costs and lower total health care costs in the Spanish NHS.
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OBJECTIVES: To assess the efﬁ ciency of the drugs used to reduce relapses in schizo-
phrenia, taking into account costs and effectiveness (measured as QALY). METHODS: 
The National Health Care System perspective and a 1 year temporal horizon have 
been used. Taking into account the last NICE review on schizophrenia1, four funda-
mental aspects related with schizophrenia management were analyzed: relapse rates, 
treatment discontinuation due to intolerable side effects, treatment discontinuation 
due to other reasons and stable patients (where the probability of remission, EPS 
syndrome, weight gain, glucose intolerance and diabetes were analyzed). The health 
care direct costs corresponding to the drug acquisition costs have been analyzed 
together with the costs of the side effects considered, the cost of the complications 
(diabetes) and the costs of hospitalary relapses (stay and drug cost) updated with data 
from Spanish Ministry of Health (2008). a Monte Carlo simulation was performed 
to obtain the cost-effectiveness ratio (euros/QALY). RESULTS: Paliperidone ER pres-
ents the lower total costs (c3060) compared to the other strategies (risperidone = 
c3206; haloperidol = c3220; olanzapine = c3903; amisulpride = c4281; aripiprazole 
= c4719). Paliperidone ER presents the higher efﬁ cacy (QALY) compared to the other 
strategies (Paliperidone ER = 0.7573; risperidone = 0.7335; haloperidol = c0.7230; 
olanzapine = c0.7474; amisulpride = c0.7320; aripiprazole = c0.7379). With these 
results, we can conclude that all the strategies are dominated by Paliperidone ER with 
a C/E ratio of 4073 (risperidone = 4382; haloperidol = 4461; olanzapine = 5.235; 
amisulpride = 5.827; aripiprazole = 6.421) CONCLUSIONS: At a willingness-to-pay 
of c30,000 per QALY all the drugs considered are cost-effective in Spain. However, 
the most efﬁ cient (more net beneﬁ c, monetary (euros) and in health—QALYs) vs. 
Haloperidol are: paliperidone ER, followed by risperidone, olanzapine, amisulpride 
and aripiprazole.
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OBJECTIVES: To evaluate the cost-effectiveness of eight ﬁ rst line antipsychotics in 
the prevention of schizophrenia relapse, from a UK National Health Service and 
Personal Social Services perspective. METHODS: A Markov model, similar to that 
used by the National Institute for Health and Clinical Excellence in the Schizophrenia 
(update) guideline (published March 2009), was developed to assess the cost per 
QALY gained for amisulpride, aripiprazole, haloperidol, olanzapine, paliperidone, 
quetiapine (XL), risperidone and zotepine. Clinical parameters were populated with 
data from mixed treatment comparisons. Patients entered the model in remission and 
could remain in remission, relapse, move to next line of therapy due to side effects, 
or discontinue for other reasons. Utilities for schizophrenia in remission and relapse 
were taken from a direct utility elicitation study conducted in a UK population. Disu-
tilities for side effects were captured. Resource use and unit costs (reference year 2009) 
were taken from published sources and a 10 year time horizon was adopted. Proba-
bilistic results were derived from 10,000 model simulations. RESULTS: The determin-
istic analysis showed quetiapine (XL) to yield the most QALYs and lowest overall 
treatment costs. Model outcomes were supported by the probabilistic analysis but 
results were characterised by uncertainty. In one scenario, drug costs for all compara-
tors bar quetiapine (XL) were set to zero. Quetiapine (XL) generated 7.051 QALYs 
compared to a range of 6.930–6.972 for other medications. Overall treatment costs 
for quetiapine (XL) were £153,104 compared to £155,766-£167,329 for other medi-
cations. Thus it was still the dominant strategy. CONCLUSIONS: The additional 
beneﬁ t of Quetiapine (XL) in terms of schizophrenia relapse prevention results in it 
being the most cost-effective of the antipsychotics assessed. Clinical efﬁ cacy is the key 
driver of cost-effectiveness in relapse prevention, hence generic antipsychotics should 
not be recommended based upon drug costs alone. Further long term trials of anti-
psychotics are required to reduce uncertainty.
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OBJECTIVES: a cost-utility analysis of agomelatine, a treatment of major depressive 
disorders in adults, was performed from the Polish public payer’s perspective (the 
National Health Fund). Agomalatine was compared with the most commonly used 
antidepressants in Poland, i.e. generic sertraline and generic venlafaxine. METHODS: 
The analysis with a time horizon of 2 years is based on a Markov model. The one-
month cycle model included the following health states: depression episode, remission, 
well and death. It also incorporated sleep disorders, discontinuation rates, discontinu-
ation symptoms and adverse drug reactions. The clinical parameters for compared 
drugs were extracted from head-to-head clinical trials. Utility and disutility estimates 
were derived from a systematic literature review. Only direct costs have been consid-
ered in order to be consistent with Polish pharmacoeconomic guidelines. Costs and 
effects were discounted at 5% and 3.5% per annum at year 1 respectively. RESULTS: 
The beneﬁ t of agomelatine over sertraline or venlafaxine was estimated at 0.005 
QALY. This effectiveness was associated with the additional costs of 491 PLN and 
149 PLN for agomelatine compared to sertraline and venlafaxine, respectively. The 
corresponding agomelatine incremental cost-utility ratios (ICURs) were therefore 
92,000 PLN/QALY and 28,000 PLN/QALY. Sensitivity analysis demonstrated that 
agomelatine ICUR remained below the three times GDP per capita threshold (33,347 
PLN for 2008) in 79.7% and 88.4% of the cases compared with sertraline and ven-
lafaxine, respectively. CONCLUSIONS: From the Polish public payer’s perspective, 
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agomelatine is a cost-effective treatment of major depressive disorders compared to 
generics of sertraline and venlafaxine.
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OF SCHIZOPHRENIA IN POLAND IN GENERAL POPULATION OF 
SCHIZOPHRENIC PATIENTS AND POPULATION OF PATIENTS 
INTOLERANT TO AT LEAST ONE OTHER ANTIPSYCHOTIC AGENT: A 
FIVE-YEAR MARKOV MODEL
Walczak J, Stelmachowski J, Obrzut G, Nogas G
Arcana Institute, Cracow, Poland
OBJECTIVES: To evaluate a cost-utility of sertindole compared with commonly used 
antipsychotic drugs in Poland: haloperidol and risperidone in the treatment of general 
population of schizophrenic patients and with risperidone in a group of patients 
intolerant to at least one other antipsychotic agent. METHODS: Cost-utility Markov 
model was constructed in ﬁ ve-year time horizon. Clinical effectiveness was assessed on 
the basis of RCTs, meta-analyses, observational studies and systematic reviews. The 
measures of effectiveness in the CUA were quality adjusted life-years (QALY) and life-
years gained (LYG). Direct medical costs were calculated from perspective of two payers 
(Polish National Health Fund and patient). Cost of: oral antipsychotic treatment, inpa-
tient care, primary health care, specialist care and adverse events treatment (extrapyra-
midal symptoms, sedation and weight gain) were included. Discount rates of 5% for 
costs and 3.5% for beneﬁ ts were used. Utilities and disutilities associated with AEs and 
relapse were derived from published literature. RESULTS: In general population of 
schizophrenic patients cost per QALY/LYG gained, using sertindole instead of risperi-
done is 97,396/26,585 PLN (c22,507/6,144) respectively; cost per QALY/LYG gained, 
using sertindole instead of haloperidol, is 82,132/20,670 PLN (c18,980/4,777) respec-
tively. In population intolerant to at least one other antipsychotic agent sertindole 
dominates risperidone (sertindole is less expensive and more effective considering both 
QALY/LYG gained). The sensitivity analysis indicated the robustness of the results. 
Obtained results are placed below the acceptability threshold (3xGDP per capita in 
Poland) which is about 105,500 PLN (c24,380). The 2009 weighted average exchange 
rate of Polish National Bank was c1 = PLN 4.3273. CONCLUSIONS: Treatment of 
schizophrenia with sertindole is a cost-effective strategy in comparison with risperi-
done and haloperidol therapy. In a group of patients intolerant to at least one other 
antipsychotic agent sertindole compared to risperidone is dominant strategy.
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OBJECTIVES: A recent meta-analysis has shown that escitalopram, a selective inhibi-
tor of serotonin reuptake, is one of the best choices when starting a treatment of 
moderate to severe major depressive disorder (MDD), with a favourable balance 
between efﬁ cacy and tolerability. Our objective was to perform an economic evalua-
tion of escitalopram versus citalopram in Israel. Citalopram is available as a generic 
drug and is included in the National Health Basket. METHODS: A decision tree model 
was used to assess the cost-utility of escitalopram versus citalopram in ﬁ rst-line treat-
ment of MDD. The model also accounted for second-, third- and fourth-line treat-
ments for patients not responding to therapy, with an overall time horizon of 12 
months. The analysis adopted a Health Maintenance Organization perspective. The 
main outcomes were quality-adjusted life-years (QALYs) and costs associated with 
local health care resource use (including drug use, and hospitalizations due to depres-
sion or suicide attempt). One-way and two-way sensitivity analyses were performed 
with the following parameters: probabilities of remission after initial and subsequent 
treatment, probabilities of relapse, suicide attempt and suicide-related death, number 
of hospitalization days due to a suicide attempt, costs of initial and subsequent treat-
ments and utility values. In addition, we used a Monte Carlo simulation. RESULTS: 
Compared to citalopram, escitalopram was more effective in terms of QALYs at a 
small incremental cost. The average QALYs of patients treated with escitalopram and 
citalopram were 0.728 and 0.720 respectively. The average cost of patients treated 
with escitalopram and citalopram were c105 and c63 respectively. The incremental 
cost-utility ratio was c5,150 (NIS23,875) per QALY. The variation of remission rates 
had the most inﬂ uence on this ratio in the sensitivity analyses. CONCLUSIONS: This 
local economic evaluation shows that compared to citalopram, escitalopram should 
be the preferred option in depression in Israel with an acceptable cost per QALY.
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OBJECTIVES: The main objective was to evaluate the consumption of antidepres-
sants, it s utilization as the basic aspect of the quality of life and to analyze the using 
of the original drugs or generics and to show the pharmacoeconomical impact of this 
group of drugs considering to it s ﬁ nancial costingness. METHODS: We used the 
analysis of consumption trend of antidepressants and the analysis of the trend of prices 
of antidepressants. We compared the original and generic market with antidepressants 
in Slovakia, we monitored and compared the prices for DDD and we evaluate the impact 
of new generics on the prices of originals as well. RESULTS: The consumption of 
antidepressants has increased because of increasing number depression illnesses which 
could be continually treated by modern antidepressants since successful treatment 
depends on relaps prevention. Such outcome could be reached by usage of the latest 
antidepressants with good compliance (escitalopram, venlafaxine, mirtazapin). Since 
2005 the consumption (packages sold) of antidepressant increased by 29% whereas 
the sales value stagnated as result of declining price. The price for daily recommended 
dosage decreased by 52.7% (from c0.80 in 2001 to c0.38 in 2008). This was inﬂ u-
enced mainly by the increasing number of generics medicaments which pushed the 
price down. In 2009 the price of original antidepressants fall by 26.4% as reason of 
generic molecules. Based on long-term surveys the similar trend could be expected also 
in the future. CONCLUSIONS: The utilization of antidepressants lead to better 
quality of life. From the pharmacoeconomical view, the development of new molecules 
goes hand in hand with the decrease of invalidation, decrease of the cost for hospi-
talization, as well as increase people ‘s ability to take care about themselves. On the 
other hand, the generic substitution leads to increase of the amount of treated patients.
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OBJECTIVES: Evaluate health care utilization among depressed patients before and 
after initiating duloxetine. METHODS: Depressed adults treated with duloxetine 
during January 1, 2006-September 30, 2007 were identiﬁ ed from the General Practice 
Research Database. All-cause health care utilization in the 12-months before and after 
treatment initiation was compared for patients and for the subset of patients with 
pre-period unexplained pain (UPain). Generalized Estimating Equation models were 
used to identify factors associated with the pre-post differences in hospitalization rates. 
Covariates included age, gender, pre-period comorbid conditions and medication use. 
RESULTS: A total of 909 patients were identiﬁ ed (mean age = 49.6; female = 67.7%), 
and 45% experienced UPain. Three-quarters of patients were prescribed a SSRI and 
11% were untreated with antidepressants before initiating duloxetine. Among 
patients, the rate of hospitalization was higher in the pre-period compared to the 
post-period (20.7% vs.16.5%, p = 0.006). There were no signiﬁ cant pre-post differ-
ences in the rates of accident & emergency visits, specialist referrals, or analgesic use. 
Among patients with UPain, fewer were hospitalized (26.2% vs. 19.1%, p = 0.003) 
or received analgesic in the post-period (77.0% vs. 71.7%, p = 0.015). Multivariate 
analysis conﬁ rmed fewer patients experienced hospitalization after duloxetine initia-
tion. All depressed patients with pre-period anxiolytic use (OR = 0.70, 95% CI, 
0.50–0.97, p = 0.033) or UPain patients with pre-period anticonvulsant use (OR = 
0.44, 95% CI, 0.21–0.91, p = 0.026) experienced a decreased hospitalization rate after 
initiating duloxetine and the magnitude of change was larger than that for patients 
not receiving these medications. All depressed patients with pre-period alcohol/drug 
dependence (OR = 1.83, 95% CI, 1.01–3.30, p = 0.045) and sleep disorder (OR = 
1.65, 95% CI, 1.05–2.59, p = 0.031) had an increase in the hospitalization rate from 
the pre- to post-period, while those without the conditions had a decreased hospitaliza-
tion rate. CONCLUSIONS: Hospitalization rates were lower following duloxetine 
initiation among depressed patients. Pre-period alcohol/drug dependence, sleep disor-
ders, anxiolytic and anticonvulsant use were associated with the pre-post difference 
in the hospitalization rate.
PMH44
AN OBSERVATIONAL STUDY OF THE BURDEN OF INFORMAL 
CAREGIVERS TO OUT-PATIENTS WITH SCHIZOPHRENIA SPECTRUM 
DISORDERS
Flyckt L1, Granström O2, Löthman A3, Jörgensen L2, Koernig T2
1Norra Stockholms Psykiatri, Danderyd, Sweden; 2AstraZeneca Nordic MC, Södertälje, 
Sweden; 3Psykiatricentrum Väst, Bromma, Sweden
OBJECTIVES: The lifetime emotional, social, and ﬁ nancial consequences experienced 
by individuals with schizophrenia spectrum disorders have signiﬁ cant effects on their 
families. Therefore, it is essential to increase the knowledge and awareness of the 
informal caregiver burden. Here, the purpose was to study objective burden (time and 
money spent), as well as subjective burden (care-related quality of life) of informal 
caregivers to patients with schizophrenia spectrum disorders. METHODS: Patients 
with schizophrenia spectrum disorders and their closest informal caregivers were 
recruited and patient- and caregiver-related characteristics and variables related to the 
provision of formal care were assessed. The subjective burden was assessed using the 
CarerQol. The objective burden was assessed prospectively during four weeks with 
daily recordings by the caregiver using diaries of the money and time spent on the 
patient. Data was analyzed using descriptive statistics. RESULTS: One-hundred and 
seven patients (53% females; mean age 43 ± 11 years) from nine centers in Sweden, 
and 118 of their closest informal care-givers (67% females; mean age 58 ± 15 years) 
entered the study. The mean (standard deviation, SD) GAF for the patients was 52 
(11). Subjective burden (CarerQol VAS) correlated positively to GAF. The mean (SD) 
time spent on caring for relatives with schizophrenia spectrum disorders was 22 (36) 
hours per week. Half of this (11 hours) was “stand-by” time and another 5 hours 
were spent on household work. Caregivers’ mean (SD) monthly expenses in support 
